for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Natco Pharma Ltd.

NATP.NS

Latest Trade

900.40INR

Change

-14.20(-1.55%)

Volume

119,215

Today's Range

892.75

 - 

921.55

52 Week Range

402.55

 - 

996.00

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Pricing

Previous Close
914.60
Open
915.10
Volume
119,215
3M AVG Volume
14.61
Today's High
921.55
Today's Low
892.75
52 Week High
996.00
52 Week Low
402.55
Shares Out (MIL)
182.19
Market Cap (MIL)
164,040.60
Forward P/E
--
Dividend (Yield %)
0.75

Next Event

Natco Pharma Ltd Annual Shareholders Meeting

Latest Developments

More

Natco Pharma Says Buys Shares In Unit Amounting To $727,100

India's Natco Pharma June-Qtr Consol Profit Falls

FDA Completes Inspection Of India's Natco Pharma's Kothur Formulation Facility

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Natco Pharma Ltd.

Natco Pharma Limited is a pharmaceutical company. The Company is engaged in developing, manufacturing and marketing finished dosage formulations (FDF) and active pharmaceutical ingredients (APIs). The Company's segments include active pharmaceuticals ingredient, finished dosage formulations, job works, pharmacy and others. The Company's product categories include Domestic Formulations, International Formulations, API's and Blockbusters. The Company's products include Alphalan, Bandrone, Bendit, Clokeran, Lenalid, Thioplan, Anastronat, Capnat, Fulvenat, Kabanat, Natdox-LP, Rapact, Temonat, X-Trant, Glatimer, Hepcinat, Natdac, Natzold, Tigi, Alprazolam, Chloroquine Phosphate, Lansoprazole, Letrozole, Granisetron, Rizatriptan IR, Imatinib, Salmeterol Xinafoate, Sertraline Form I, Ibandronate Sodium Monohydrate, Pantoprazole Sodium Sesquihydrate, Ondansetron Hydrochloride (Injectable Grade), Daclatasvir and Glatiramer Acetate. The Company manufactures over 20 products under contract.

Industry

Biotechnology & Drugs

Contact Info

Natco House, Road No 2, Banjara Hills

500034

India

+91.40.23547532

http://www.natcopharma.co.in/

Executive Leadership

V. C. Nannapaneni

Executive Chairman of the board, Managing Director

Rajeev Nannapaneni

Executive Vice Chairman of the Board, Chief Executive Officer

S. V. V. N. Appa Rao

Chief Financial Officer, Vice President - Finance and Accounts

Linga Rao

President - Technical Affairs, Director

P. S. R. K. Prasad

Executive Vice President - Corporate Engineering Services, Additional Wholetime Director

Key Stats

2.20 mean rating - 15 analysts
Sell
Hold
Buy
Revenue (MM, INR)

2018

21.8K

2019

20.9K

2020

19.2K

2021(E)

22.1K
EPS (INR)

2018

39.130

2019

34.870

2020

25.260

2021(E)

29.629
Price To Earnings (TTM)
37.30
Price To Sales (TTM)
8.26
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
30.20
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

BRIEF-Natco Pharma Donating Chloroquine Phosphate Tablets For Columbia University's Trial

* DONATING CHLOROQUINE PHOSPHATE TABLETS, THROUGH U.S. MARKETING PARTNER, TO COLUMBIA UNIVERSITY

BRIEF-Natco Pharma Ltd's Vizag Formulation Facility Gets U.S. FDA Approval

* VIZAG FORMULATION FACILITY RECEIVES USFDA APPROVAL Source text for Eikon: Further company coverage:

BRIEF-FDA Completes Inspection Of India's Natco Pharma's Kothur Formulation Facility

* U.S. FDA COMPLETES INSPECTION OF NATCO'S KOTHUR FORMULATION FACILITY

BRIEF-India's Natco Pharma Dec Quarter Consol Profit Falls

* DEC QUARTER CONSOL NET PROFIT 1.05 BILLION RUPEES VERSUS 1.6 BILLION RUPEES YEAR AGO

MEDIA-Natco Pharma launches cut price versions of cancer drug ibrutinib in India - Economic Times

- Source link https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/natco-launches-cut-price-versions-of-cancer-drug-ibrutinib-in-india/articleshow/72894811.cms

MEDIA-Delhi HC grants India's Natco Pharma interim relief in  BMS patents case - Mint

- Note: Reuters has not verified this story and does not vouch for its accuracy

BUZZ-India's Natco Pharma jumps as U.S. court affirms Teva's patents invalid

** Shares of India's Natco Pharma Ltd climb as much as 8.3 pct to 734 rupees, their biggest intraday pct gain since Oct. 5, 2017

BRIEF-Natco Pharma Files ANDA to U.S. FDA For Sofosbuvir Tablets

* SAYS FILED AN ABBREVIATED NEW DRUG APPLICATION FOR SOFOSBUVIR TABLETS, 400MG, WITH U.S. FDA

BRIEF-Gilead: Natco And Teva Requested FDA Permission To Make Generic Version Of Sovaldi - SEC Filing

* GILEAD SCIENCES INC SAYS IN FEBRUARY 2018, CO RECEIVED NOTICES FROM NATCO PHARMA LIMITED AND TEVA PHARMA - SEC FILING

BRIEF-Natco Pharma Says Co's Mekaguda Facility Undergoing Routine U.S. FDA Inspection

* NATCO PHARMA CLARIFIES ON NEWS ITEM ON US FDA INSPECTION AT CO'S MEKAGUDA FACILITY IN TELANGANA

BRIEF-India's Natco Pharma Dec-Qtr Consol Profit Rises

* DEC QUARTER CONSOL NET PROFIT 2.18 BILLION RUPEES VERSUS PROFIT 1.95 BILLION RUPEES YEAR AGO

BRIEF-Natco Pharma Launches Tafnat, Tenofovir Alafenamide Tablets In India

* SAYS NATCO LAUNCHES TAFNAT, TENOFOVIR ALAFENAMIDE TABLETS, FOR TREATMENT OF CHRONIC HEPATITIS B, IN INDIA Source text for Eikon: Further company coverage:

BRIEF-Natco Pharma Approved Allocation Of 10 Mln Shares At 915 Rupees/Share Upon Closure Of QIP

* NATCO PHARMA - APPROVED ALLOCATION OF 10 MILLION SHARES AT ISSUE PRICE OF 915 RUPEES PER SHARE UPON CLOSURE OF QIP Source text: http://bit.ly/2zbT0ZA Further company coverage:

BRIEF-Natco Pharma Approves QIP Floor Price Of 937.63 Rupees/Shr

* SAYS APPROVED QIP FLOOR PRICE OF 937.63 RUPEES PER SHARE Source text: http://bit.ly/2AJA9El Further company coverage:

BRIEF-India's Natco Pharma Sept-qtr consol profit up about 28 pct

* Sept quarter consol net profit 848 million rupees versus profit of 665 million rupees last year

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up